British Journal of Clinical Pharmacology

OCT 11, 2026 · JOURNAL ARTICLE

Triangulation of dispensing and wastewater data for surveillance during lisdexamfetamine shortages: A descriptive time series analysis

British Journal of Clinical Pharmacology

Abstract Aims Lisdexamfetamine, a long‐acting stimulant for attention‐deficit hyperactivity disorder (ADHD), has experienced widespread shortages in Australia since late 2023, rais

SEP 21, 2026 · JOURNAL ARTICLE

Pharmacokinetics and safety of a modified‐release psilocybin formulation: A SAD Phase I trial in normal‐weight and overweight/obese participants

British Journal of Clinical Pharmacology

Aims This study aimed to evaluate the safety, tolerability and pharmacokinetics of a novel oral modified‐release psilocybin formulation (REL‐P11) in normal‐weight and overweight/ob

SEP 17, 2026 · JOURNAL ARTICLE

Targeting the cardiohepatic–metabolic axis: GLP‐1–based and incretin multi‐agonist therapies in MASH

British Journal of Clinical Pharmacology

Metabolic dysfunction‐associated steatohepatitis (MASH) has emerged as a leading cause of chronic liver disease worldwide and is increasingly recognized as a systemic metabolic‐inf

SEP 10, 2026 · JOURNAL ARTICLE

Long‐acting cabotegravir and rilpivirine in people with HIV and cancer: Virological eligibility and DDI considerations

British Journal of Clinical Pharmacology

Retrospective single-centre assessment of theoretical eligibility and drug-drug interactions; descriptive analysis without a comparator, control group, or clinical outcome measurement.

SEP 8, 2026 · JOURNAL ARTICLE

Alpha lipoic acid for prevention of radiation‐induced dermatitis in breast cancer patients: A randomized‐controlled trial

British Journal of Clinical Pharmacology

A single-centre RCT with modest sample size (n=40) and surrogate endpoint (dermatitis grading) showing benefit of ALA over control, needing confirmation in larger trials before clinical adoption.

SEP 6, 2026 · JOURNAL ARTICLE

The potential impact of H1 antihistamines on clinical outcomes in NSCLC patients undergoing EGFR‐TKIs treatment

British Journal of Clinical Pharmacology

Retrospective cohort study with adjusted hazard ratios showing substantial associations between H1-antihistamine use and improved TTF and mortality in NSCLC patients on EGFR-TKIs, but observational design precludes causal inference and requires prospective confirmation.